Research programme: anticoagulant - PepTx

Drug Profile

Research programme: anticoagulant - PepTx

Alternative Names: PTX003; βpep peptide PTX003

Latest Information Update: 25 Mar 2008

Price : $50

At a glance

  • Originator University of Minnesota
  • Developer PepTx; University of Minnesota
  • Class
  • Mechanism of Action Protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Blood coagulation disorders; Thrombosis

Most Recent Events

  • 25 Mar 2008 Preclinical development is ongoing
  • 21 May 2007 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top